세계의 약물감시 시장(2025-2035년): 산업 분석, 시장 규모, 점유율, 성장, 동향, 예측 - 단계별(전임상, 1상, 2상, 3상, 4상), 유형별, 치료영역별, 최종용도별, 기타

Pharmacovigilance Market - Scope of Report

TMR's report on the global pharmacovigilance market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2025 to 2035. The report provides revenue of the global pharmacovigilance market for the period 2019-2035, considering 2025 as the base year and 2035 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global pharmacovigilance market from 2025 to 2035.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the pharmacovigilance market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global pharmacovigilance market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global pharmacovigilance market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global pharmacovigilance market.

The report delves into the competitive landscape of the global pharmacovigilance market. Key players operating in the global pharmacovigilance market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global pharmacovigilance market profiled in this report.

Key Questions Answered in Global pharmacovigilance Market Report:

• What is the sales/revenue generated by pharmacovigilance across all regions during the forecast period?
• What are the opportunities in the global pharmacovigilance market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2035?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?

Pharmacovigilance Market - Research Objectives and Research Approach

The comprehensive report on the global pharmacovigilance market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global pharmacovigilance market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2035 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global pharmacovigilance market.

Table of Contents

1. Preface

• 1.1. Market Definition and Scope
• 1.2. Market Segmentation
• 1.3. Key Research Objectives
• 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Pharmacovigilance Market

4. Market Overview

• 4.1. Introduction
  • 4.1.1. Segment Definition
• 4.2. Overview
• 4.3. Market Dynamics
  • 4.3.1. Drivers
  • 4.3.2. Restraints
  • 4.3.3. Opportunities
• 4.4. Global Pharmacovigilance Market Analysis and Forecast, 2020 to 2035
  • 4.4.1. Market Revenue Projections (US$ Mn)

5. Key Insights

• 5.1. Overview of Government Initiatives in Safe Medicine Use
• 5.2. Rate of Adverse Drug Reactions By Key Region/Countries
• 5.3. Regulatory Scenario by Region/Country
• 5.4. Role of Pharmacovigilance during Drug Development Process
• 5.5. Comparative Analysis of Report used in Pharmacovigilance
• 5.6. Funding and Investments
• 5.7. Key Industry Events (Mergers, Acquisitions, Partnerships, Collaborations, etc.)
• 5.8. PORTER's Five Forces Analysis
• 5.9. PESTEL Analysis
• 5.10. Value Chain Analysis

6. Global Pharmacovigilance Market Analysis and Forecast, by Phase

• 6.1. Introduction & Definition
• 6.2. Key Findings/Developments
• 6.3. Market Value Forecast, by Phase, 2020 to 2035
  • 6.3.1. Pre-clinical
  • 6.3.2. Phase I
  • 6.3.3. Phase II
  • 6.3.4. Phase III
  • 6.3.5. Phase IV
• 6.4. Market Attractiveness Analysis, by Phase

7. Global Pharmacovigilance Market Analysis and Forecast, by Type

• 7.1. Introduction & Definition
• 7.2. Key Findings/Developments
• 7.3. Market Value Forecast, by Type, 2020 to 2035
  • 7.3.1. Spontaneous Reporting
  • 7.3.2. Targeted Reporting
  • 7.3.3. Cohort Event Monitoring
  • 7.3.4. Epidemiological Studies
  • 7.3.5. Post-Marketing Surveillance
• 7.4. Market Attractiveness Analysis, by Type

8. Global Pharmacovigilance Market Analysis and Forecast, by Delivery Mode

• 8.1. Introduction & Definition
• 8.2. Key Findings/Developments
• 8.3. Market Value Forecast, by Delivery Mode, 2020 to 2035
  • 8.3.1. In-house
  • 8.3.2. Contract Outsourcing
• 8.4. Market Attractiveness Analysis, by Delivery Mode

9. Global Pharmacovigilance Market Analysis and Forecast, by Therapeutic Area

• 9.1. Introduction & Definition
• 9.2. Key Findings/Developments
• 9.3. Market Value Forecast, by Therapeutic Area, 2020 to 2035
  • 9.3.1. Oncology
  • 9.3.2. Neurology
  • 9.3.3. Cardiology
  • 9.3.4. Respiratory Systems
  • 9.3.5. Autoimmune Diseases
  • 9.3.6. Others
• 9.4. Market Attractiveness Analysis, by Therapeutic Area

10. Global Pharmacovigilance Market Analysis and Forecast, by End-user

• 10.1. Introduction & Definition
• 10.2. Key Findings/Developments
• 10.3. Market Value Forecast, by End-user, 2020 to 2035
  • 10.3.1. Pharmaceutical & Biotechnology Companies
  • 10.3.2. Contract Research Organizations (CROs)
  • 10.3.3. Others
• 10.4. Market Attractiveness Analysis, by End-user

11. Global Pharmacovigilance Market Analysis and Forecast, by Region

• 11.1. Key Findings
• 11.2. Market Value Forecast, by Region, 2020 to 2035
  • 11.2.1. North America
  • 11.2.2. Europe
  • 11.2.3. Asia Pacific
  • 11.2.4. Latin America
  • 11.2.5. Middle East & Africa
• 11.3. Market Attractiveness Analysis, by Region

12. North America Pharmacovigilance Market Analysis and Forecast

• 12.1. Introduction
  • 12.1.1. Key Findings
• 12.2. Market Value Forecast, by Phase, 2020 to 2035
  • 12.2.1. Pre-clinical
  • 12.2.2. Phase I
  • 12.2.3. Phase II
  • 12.2.4. Phase III
  • 12.2.5. Phase IV
• 12.3. Market Value Forecast, by Type, 2020 to 2035
  • 12.3.1. Spontaneous Reporting
  • 12.3.2. Targeted Reporting
  • 12.3.3. Cohort Event Monitoring
  • 12.3.4. Epidemiological Studies
  • 12.3.5. Post-Marketing Surveillance
• 12.4. Market Value Forecast, by Delivery Mode, 2020 to 2035
  • 12.4.1. In-house
  • 12.4.2. Contract Outsourcing
• 12.5. Market Value Forecast, by Therapeutic Area, 2020 to 2035
  • 12.5.1. Oncology
  • 12.5.2. Neurology
  • 12.5.3. Cardiology
  • 12.5.4. Respiratory Systems
  • 12.5.5. Autoimmune Diseases
  • 12.5.6. Others
• 12.6. Market Value Forecast, by End-user, 2020 to 2035
  • 12.6.1. Pharmaceutical & Biotechnology Companies
  • 12.6.2. Contract Research Organizations (CROs)
  • 12.6.3. Others
• 12.7. Market Value Forecast, by Country, 2020 to 2035
  • 12.7.1. U.S.
  • 12.7.2. Canada
• 12.8. Market Attractiveness Analysis
  • 12.8.1. By Phase
  • 12.8.2. By Type
  • 12.8.3. By Delivery Mode
  • 12.8.4. By Therapeutic Area
  • 12.8.5. By End-user
  • 12.8.6. By Country

13. Europe Pharmacovigilance Market Analysis and Forecast

• 13.1. Introduction
  • 13.1.1. Key Findings
• 13.2. Market Value Forecast, by Phase, 2020 to 2035
  • 13.2.1. Pre-clinical
  • 13.2.2. Phase I
  • 13.2.3. Phase II
  • 13.2.4. Phase III
  • 13.2.5. Phase IV
• 13.3. Market Value Forecast, by Type, 2020 to 2035
  • 13.3.1. Spontaneous Reporting
  • 13.3.2. Targeted Reporting
  • 13.3.3. Cohort Event Monitoring
  • 13.3.4. Epidemiological Studies
  • 13.3.5. Post-Marketing Surveillance
• 13.4. Market Value Forecast, by Delivery Mode, 2020 to 2035
  • 13.4.1. In-house
  • 13.4.2. Contract Outsourcing
• 13.5. Market Value Forecast, by Therapeutic Area, 2020 to 2035
  • 13.5.1. Oncology
  • 13.5.2. Neurology
  • 13.5.3. Cardiology
  • 13.5.4. Respiratory Systems
  • 13.5.5. Autoimmune Diseases
  • 13.5.6. Others
• 13.6. Market Value Forecast, by End-user, 2020 to 2035
  • 13.6.1. Pharmaceutical & Biotechnology Companies
  • 13.6.2. Contract Research Organizations (CROs)
  • 13.6.3. Others
• 13.7. Market Value Forecast, by Country/Sub-region, 2020 to 2035
  • 13.7.1. Germany
  • 13.7.2. UK
  • 13.7.3. France
  • 13.7.4. Italy
  • 13.7.5. Spain
  • 13.7.6. Rest of Europe
• 13.8. Market Attractiveness Analysis
  • 13.8.1. By Phase
  • 13.8.2. By Type
  • 13.8.3. By Delivery Mode
  • 13.8.4. By Therapeutic Area
  • 13.8.5. By End-user
  • 13.8.6. By Country/Sub-region

14. Asia Pacific Pharmacovigilance Market Analysis and Forecast

• 14.1. Introduction
  • 14.1.1. Key Findings
• 14.2. Market Value Forecast, by Phase, 2020 to 2035
  • 14.2.1. Pre-clinical
  • 14.2.2. Phase I
  • 14.2.3. Phase II
  • 14.2.4. Phase III
  • 14.2.5. Phase IV
• 14.3. Market Value Forecast, by Type, 2020 to 2035
  • 14.3.1. Spontaneous Reporting
  • 14.3.2. Targeted Reporting
  • 14.3.3. Cohort Event Monitoring
  • 14.3.4. Epidemiological Studies
  • 14.3.5. Post-Marketing Surveillance
• 14.4. Market Value Forecast, by Delivery Mode, 2020 to 2035
  • 14.4.1. In-house
  • 14.4.2. Contract Outsourcing
• 14.5. Market Value Forecast, by Therapeutic Area, 2020 to 2035
  • 14.5.1. Oncology
  • 14.5.2. Neurology
  • 14.5.3. Cardiology
  • 14.5.4. Respiratory Systems
  • 14.5.5. Autoimmune Diseases
  • 14.5.6. Others
• 14.6. Market Value Forecast, by End-user, 2020 to 2035
  • 14.6.1. Pharmaceutical & Biotechnology Companies
  • 14.6.2. Contract Research Organizations (CROs)
  • 14.6.3. Others
• 14.7. Market Value Forecast, by Country/Sub-region, 2020 to 2035
  • 14.7.1. China
  • 14.7.2. Japan
  • 14.7.3. India
  • 14.7.4. Australia & New Zealand
  • 14.7.5. Rest of Asia Pacific
• 14.8. Market Attractiveness Analysis
  • 14.8.1. By Phase
  • 14.8.2. By Type
  • 14.8.3. By Delivery Mode
  • 14.8.4. By Therapeutic Area
  • 14.8.5. By End-user
  • 14.8.6. By Country/Sub-region

15. Latin America Pharmacovigilance Market Analysis and Forecast

• 15.1. Introduction
  • 15.1.1. Key Findings
• 15.2. Market Value Forecast, by Phase, 2020 to 2035
  • 15.2.1. Pre-clinical
  • 15.2.2. Phase I
  • 15.2.3. Phase II
  • 15.2.4. Phase III
  • 15.2.5. Phase IV
• 15.3. Market Value Forecast, by Type, 2020 to 2035
  • 15.3.1. Spontaneous Reporting
  • 15.3.2. Targeted Reporting
  • 15.3.3. Cohort Event Monitoring
  • 15.3.4. Epidemiological Studies
  • 15.3.5. Post-Marketing Surveillance
• 15.4. Market Value Forecast, by Delivery Mode, 2020 to 2035
  • 15.4.1. In-house
  • 15.4.2. Contract Outsourcing
• 15.5. Market Value Forecast, by Therapeutic Area, 2020 to 2035
  • 15.5.1. Oncology
  • 15.5.2. Neurology
  • 15.5.3. Cardiology
  • 15.5.4. Respiratory Systems
  • 15.5.5. Autoimmune Diseases
  • 15.5.6. Others
• 15.6. Market Value Forecast, by End-user, 2020 to 2035
  • 15.6.1. Pharmaceutical & Biotechnology Companies
  • 15.6.2. Contract Research Organizations (CROs)
  • 15.6.3. Others
• 15.7. Market Value Forecast, by Country/Sub-region, 2020 to 2035
  • 15.7.1. Brazil
  • 15.7.2. Mexico
  • 15.7.3. Rest of Latin America
• 15.8. Market Attractiveness Analysis
  • 15.8.1. By Phase
  • 15.8.2. By Type
  • 15.8.3. By Delivery Mode
  • 15.8.4. By Therapeutic Area
  • 15.8.5. By End-user
  • 15.8.6. By Country/Sub-region

16. Middle East & Africa Pharmacovigilance Market Analysis and Forecast

• 16.1. Introduction
  • 16.1.1. Key Findings
• 16.2. Market Value Forecast, by Phase, 2020 to 2035
  • 16.2.1. Pre-clinical
  • 16.2.2. Phase I
  • 16.2.3. Phase II
  • 16.2.4. Phase III
  • 16.2.5. Phase IV
• 16.3. Market Value Forecast, by Type, 2020 to 2035
  • 16.3.1. Spontaneous Reporting
  • 16.3.2. Targeted Reporting
  • 16.3.3. Cohort Event Monitoring
  • 16.3.4. Epidemiological Studies
  • 16.3.5. Post-Marketing Surveillance
• 16.4. Market Value Forecast, by Delivery Mode, 2020 to 2035
  • 16.4.1. In-house
  • 16.4.2. Contract Outsourcing
• 16.5. Market Value Forecast, by Therapeutic Area, 2020 to 2035
  • 16.5.1. Oncology
  • 16.5.2. Neurology
  • 16.5.3. Cardiology
  • 16.5.4. Respiratory Systems
  • 16.5.5. Autoimmune Diseases
  • 16.5.6. Others
• 16.6. Market Value Forecast, by End-user, 2020 to 2035
  • 16.6.1. Pharmaceutical & Biotechnology Companies
  • 16.6.2. Contract Research Organizations (CROs)
  • 16.6.3. Others
• 16.7. Market Value Forecast, by Country/Sub-region, 2020 to 2035
  • 16.7.1. GCC Countries
  • 16.7.2. South Africa
  • 16.7.3. Rest of Middle East & Africa
• 16.8. Market Attractiveness Analysis
  • 16.8.1. By Phase
  • 16.8.2. By Type
  • 16.8.3. By Delivery Mode
  • 16.8.4. By Therapeutic Area
  • 16.8.5. By End-user
  • 16.8.6. By Country/Sub-region

17. Competition Landscape

• 17.1. Market Player - Competition Matrix (By Tier and Size of Companies)
• 17.2. Market Share Analysis, by Company (2024)
• 17.3. Company Profiles
  • 17.3.1. Accenture
    • 17.3.1.1. Company Overview
    • 17.3.1.2. Financial Overview
    • 17.3.1.3. Product Portfolio
    • 17.3.1.4. Business Strategies
    • 17.3.1.5. Recent Developments
  • 17.3.2. IQVIA Inc.
    • 17.3.2.1. Company Overview
    • 17.3.2.2. Financial Overview
    • 17.3.2.3. Product Portfolio
    • 17.3.2.4. Business Strategies
    • 17.3.2.5. Recent Developments
  • 17.3.3. Cognizant
    • 17.3.3.1. Company Overview
    • 17.3.3.2. Financial Overview
    • 17.3.3.3. Product Portfolio
    • 17.3.3.4. Business Strategies
    • 17.3.3.5. Recent Developments
  • 17.3.4. Linical
    • 17.3.4.1. Company Overview
    • 17.3.4.2. Financial Overview
    • 17.3.4.3. Product Portfolio
    • 17.3.4.4. Business Strategies
    • 17.3.4.5. Recent Developments
  • 17.3.5. ArisGlobal
    • 17.3.5.1. Company Overview
    • 17.3.5.2. Financial Overview
    • 17.3.5.3. Product Portfolio
    • 17.3.5.4. Business Strategies
    • 17.3.5.5. Recent Developments
  • 17.3.6. ITClinical
    • 17.3.6.1. Company Overview
    • 17.3.6.2. Financial Overview
    • 17.3.6.3. Product Portfolio
    • 17.3.6.4. Business Strategies
    • 17.3.6.5. Recent Developments
  • 17.3.7. ICON plc.
    • 17.3.7.1. Company Overview
    • 17.3.7.2. Financial Overview
    • 17.3.7.3. Product Portfolio
    • 17.3.7.4. Business Strategies
    • 17.3.7.5. Recent Developments
  • 17.3.8. TAKE Solutions Limited
    • 17.3.8.1. Company Overview
    • 17.3.8.2. Financial Overview
    • 17.3.8.3. Product Portfolio
    • 17.3.8.4. Business Strategies
    • 17.3.8.5. Recent Developments
  • 17.3.9. Parexel International (MA) Corporation
    • 17.3.9.1. Company Overview
    • 17.3.9.2. Financial Overview
    • 17.3.9.3. Product Portfolio
    • 17.3.9.4. Business Strategies
    • 17.3.9.5. Recent Developments
  • 17.3.10. Wipro
    • 17.3.10.1. Company Overview
    • 17.3.10.2. Financial Overview
    • 17.3.10.3. Product Portfolio
    • 17.3.10.4. Business Strategies
    • 17.3.10.5. Recent Developments
  • 17.3.11. United BioSource LLC
    • 17.3.11.1. Company Overview
    • 17.3.11.2. Financial Overview
    • 17.3.11.3. Product Portfolio
    • 17.3.11.4. Business Strategies
    • 17.3.11.5. Recent Developments
  • 17.3.12. Ergomed Group
    • 17.3.12.1. Company Overview
    • 17.3.12.2. Financial Overview
    • 17.3.12.3. Product Portfolio
    • 17.3.12.4. Business Strategies
    • 17.3.12.5. Recent Developments
  • 17.3.13. Quanticate
    • 17.3.13.1. Company Overview
    • 17.3.13.2. Financial Overview
    • 17.3.13.3. Product Portfolio
    • 17.3.13.4. Business Strategies
    • 17.3.13.5. Recent Developments